Repatha Only $49 million Worldwide for Q1 2017

This perfectly sums up how I feel. Very few territories meeting expectations now. Goals are completely unattainable!

 

- Base products losing share and not growing except with price increases ( exception is prolia)
- growth products in Repatha and Kyprolis are disappointing and severely not meeting expectations
- near term pipeline consist of Romo and Migraine drug
- romo in competitive and limited market with inferior data
- migraine with non differentiated data and 3rd in class status but will enjoy a short 1-2 year market lead
- amgen splits the commercial with Novartis so limited upside but was needed since amgen has no neuro experience and recent launch letdowns have made Bob bradway wary of Amgen commercial team
- the only thing left is for amgen to do some buying of companies or a mega merger

 

Lies!!!

Amgen will hire assassins to take out and kill all biologic biosimilars to ensure they cannot make the drug and delay market entry.

We will then kill all competitors by killing all mfg, sales, marketing so we will have then Ly product and on the market.

This will result in being a $40B company. The $30B in cash can Nuke all other big pharma like Genentech and Abbvie.

 

Repatha tires continue to spin in the sand!

 

This story of this drug is simply a testament to the leadership of TH.

 

The pressure is coming! Pulling the plug on osteo drug sent stock into a nose dive. Expect the trimming to start shortly

 

You better have your resumes up to date if the contract team is let go cuz that means the ship is going down fast. Now get off Cafe Pharma and drive some business ya bunch of F-ing whiners! You're Amgen! The cream de la cream. HA!

 

The pressure is coming? The pressure has been intense since I signed up for this gig 2.5 years ago. They had a way of even making disease state awareness stressful. Too much micromanaging and fire drills. What ever happened to making smart decisions for long term effects. This company changes strategy more than you have to charge an Apple Watch.

 

There was a 15% decline in 1stQtr Enbrel sales year over year. They are being whipped very hard to turn it around. If they do not correct the trajectory it is going to effect our total revenue. This definitely points to a greater emphasis on increasing Repatha sales to offset the Enbrel loss. However, our brilliant leaders will not give us more resources to accomplish this. We are going to see a shrinking budget, greater focus on reach and frequency, reduction in head count, and other drastic measures to cut costs. Prepare for the broiler phase to be initiated.